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Introduction  
The International Committee of Medical Journal Editors (ICMJE) has issued the latest of a series of 
calls promoting the sharing of individual patient data (IPD) from randomised trials.1 Valuable as 
IPD sharing can be,2 discussion about it has hijacked the broader conversation about data sharing 
and trial transparency. Numerous prominent editorials and commentaries have discussed data 
sharing passionately,3–5 however the debate is mostly focused on IPD. For example, we analysed all 
76 articles published in the six leading general medical journals that had “data” and “sharing” in 
their title and were about clinical trials. In 64 (84%) articles, the content was focussed on IPD and 
did not mention any of the other components of trial transparency (see eAppendix 1). While trial 
transparency is a major impetus of data sharing, sharing just IPD does not achieve this. Trial 
transparency requires a data sharing ‘package’, which begins with trial registration and contains 
other elements such as protocols, summary results, and trial materials.  
 
Because IPD considerations have dominated the trial transparency agenda, much discussion has 
focused on the complexities and practical problems associated with IPD sharing and the processes 
and systems needed for responsible data sharing.5–8 However, many of the data sharing activities 
that are needed for trial transparency are not complex. We believe that trying to solve the complex 
issues around IPD availability should not eclipse or distract from a more pressing problem: the 
unavailability of even summary data and protocols from all controlled trials. Current estimates are 
that around 85% of research is avoidably “wasted” due to design flaws, poor conduct, non-
publication, and poor reporting.9 Focusing efforts and attention on making IPD accessible might 
paradoxically exacerbate this waste in research. We examine simpler and more cost-efficient 
activities that should be prioritised. These are summarised in Figure 1, and expand upon a 
previously-published trial reporting system.10  
 
Priorities 
1. Prospective trial registration  
About one in two trials is never published.11 In 2005 the ICMJE introduced prospective registration 
as an attempt to minimise selective reporting. However many trials are still not prospectively 
registered, even those published in high-impact journals,12 and fewer than half of the journals that 
publish reports of trials enforce this requirement.13 As well as the problems of selective publication 
of trials and outcomes, unregistered trials, or those registered after the completion date, tend to yield 
larger estimates of treatment effects than those registered prior to completion.14  
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Trial registration is simple and inexpensive, and uses existing systems, such as ClinicalTrials.gov. 
The AllTrials campaign has been championing trial registration for all trials, as well as calling for 
summary results, and a full report (full methods, analyses, and results) to be publicly available, but 
the campaign has stated explicitly “We do not call for individual patient data to be made publicly 
available”.15 The campaign has also highlighted ways in which trial registration could be improved. 
Although the World Health Organisation has fostered the development of an international standard 
for Trial Registration Data,16 minimum requirements are neither sufficient nor enforced.  
  
2. Summary results reported  
In 2007, ClinicalTrials.gov began requiring, as part of the Food and Drug Administration 
Amendments Act (FDAAA) that summary results of certain categories of trials (for example, trials 
of currently approved medicines, with at least one site in the United States (US), or conducted as 
part of a marketing approval application) be submitted within 12 months of the completion of data 
collection, whether or not the trial had been formally published in a journal. The information 
required includes tabular summaries of participant flow, baseline characteristics, pre-specified 
outcome measure values and adverse events by study arm or comparison group, and statistical 
analyses. However, subsequent audits have revealed poor attention to these requirements, with only 
about one trial in five complying.17 Furthermore, although the US Food and Drug Administration is 
entitled to impose fines of $10,000 a day for non-compliance, penalties have never been levied. In 
September 2016, partly in response to low compliance and to remove ambiguity about the 
requirements, a final rule to the earlier FDAAA was announced.18 At the same time, the US 
National Institutes of Health (NIH) issued a policy requiring all NIH-funded trials (including of 
interventions that are not covered by the FDAAA requirements, such as non-drug interventions) to 
submit registration and summary results to ClinicalTrials.gov. Compliance with this NIH policy and 
clarification of the FDAAA rule will need evaluation.  
 
Posting a summary of trial results enables key information to be publicly and promptly available, 
including to those endeavouring to keep systematic reviews up to date. Indeed, information on 
participant flow, efficacy, and adverse events in trials is reported more promptly and in a higher 
proportion of trials in trial registries than in most reports published in journals.19,20 It is reasonably 
simple to do, requires a similar format to that required for publication in a journal article, can utilise 
existing platforms, and is not regarded as prior publication by the ICMJE. Pfizer has estimated that 
it takes between 5 and 60 hours of person-time to post a summary of the results of a completed trial 
to ClinicalTrials.gov.21 Assuming an average of 40 hours at $50 per hour, the cost per trial would be 
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about US$2,000. This is a trivial sum in the context of cost estimates of US$42,000 per participant 
for running a trial.22  
 
Despite the benefits to trial transparency and the comparatively small time investment, 
ClinicalTrials.gov is currently the only public registry that has data fields to accept summary results 
for any registered trial. The European Clinical Trials Database also began requiring summary 
results in July 2014, but only accepts results of trials of drugs that are within the regulatory scope of 
the European Medicines Agency. It is too early to assess compliance with this requirement. 
 
3. Trial protocol available 
The minimum details currently required by trial registries are insufficient to enable confident 
interpretation and use of trial results in clinical practice. Good trial protocols facilitate full reporting 
and proper conduct of trials,23 however, they are not publicly available for most trials.  
 
Inclusion of protocols in trial registries would be ideal, but this is currently rare. New regulations in 
the US24 require that those conducting trials of drugs and devices (but not other non-drug 
interventions) submit a copy of the protocol and statistical analysis plan for public posting. 
Although this requirement is a welcome development, it only applies to a proportion of the world’s 
trials and it remains to be seen whether it will be enforced. Some registries allow protocols to be 
uploaded as PDFs (for example, the ISRCTN registry, and from June 2017, ClinicalTrials.gov will 
allow protocols in English), and others allow links to protocols published in journals or posted on 
other sites (for example, those for trials funded through the NIHR Health Technology Assessment 
Programme), but most registries do not offer either of these options.  
 
4. Other trial materials  
There are many trial materials that are important for interpreting, using, and replicating trials, 
however this information is rarely included in publications or otherwise made public. This includes:  
patient and investigator information (such as consent forms and trial information sheets), statistical 
analysis plans, blank case report forms, and reproducible descriptions of measurements and 
interventions. While ideally these materials should be included in protocols, they usually are not. 
Additionally, after the protocol is complete and the trial has commenced, modifications can occur to 
some of this information (such as intervention details and data analysis plans) and these 
modifications and updated materials should be available.  
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As an example of the consequences of missing trial materials, consider adequate descriptions of the 
interventions assessed in trials. Without full details, interventions shown to be useful cannot be taken 
up by health professionals, patients, other researchers, and policy makers.15 Most analyses have found 
that over half of the studies examined have incomplete intervention descriptions (with intervention 
materials the most frequently missing component),26,27 and these and other trial materials are 
generally hard to access, even on request.26,28 The result is that studies supported by the public and to 
which patients have contributed are unusable and not replicable by others, with the entire trial 
investment becoming a sunk-cost. Another example of why access to other types of trial materials 
can be important is the need for transparency of consent forms and patient information sheets when 
participants who are assigned to control groups appear to have received care below accepted 
standards.  
 
Initiatives to improve access to additional materials have included guidance on descriptions of 
interventions25 and public sharing platforms to facilitate sharing of trial materials,29 but these 
developments have not yet received mainstream support. As with summary results, trial materials 
should be publicly available after trial completion, yet discussion is needed to agree how to achieve 
this. Many registries do not accept PDF uploads, only some registries allow web links to be 
provided, most trials do not have websites, and links to journal online supplementary materials and 
other websites are too often unreliable.  
 
Clinical Study Reports 
For some trials (usually for interventions which require regulation or licensing), clinical study 
reports (CSR) are produced as the full trial report. CSRs contain many of the other elements of the 
trial transparency ‘package’ that have been described in this article (such as detailed protocols, 
statistical analysis plans, and efficacy and safety evaluations).30 As such, where CSRs exist, they 
can make an important contribution towards trial transparency and should be made publicly 
available, even if it is without the IPD that they sometimes contain.   
 
All trials for any and all interventions 
Calls to improve access to trial data tend to focus on drug, biologic, and medical device trials, 
probably because regulatory approval is required for these interventions. Despite views to the 
contrary,31 these initiatives apply equally to trials of non-regulated interventions. About 40% of 
published reports of randomised trials are concerned with the effects of non-regulated 
interventions.32 Furthermore, trials of non-regulated interventions (such as exercise and diet, 
behavioural, psychological, and physical therapies, and public health interventions) are significantly 
6 
 
less likely to be registered,12 more likely to have inadequate intervention descriptions,26 and are not 
covered by governing bodies able to require that summary results are posted. The priorities outlined 
in this article apply to all trials of any interventions, not only to trials of drugs, biologics, and 
devices. 
 
Conclusion 
We believe that calls to make IPD available are usually made to encourage transparency and enable 
use, reuse, and replication of research. However, these worthy objectives will not be achieved 
without addressing the problems stemming directly from poor documentation and reporting of 
research. The potential contribution of IPD will remain unrealised while so much research is poorly 
reported, irreplicable, and uninterpretable because of selective or deceptive reporting. Trial 
registries are the only currently feasible mechanism by which the priorities listed in this article can 
be achieved. Beyond registration of trials, all registries could create fields for summary results to be 
entered as ClinicalTrials.gov has. Additionally, all trialists could be required to upload protocols 
and other trial materials. This would make all trial information readily accessible in the one 
location, as well as enable monitoring and reporting of compliance with providing trial information.  
 
We are strongly supportive of encouraging IPD availability and acknowledge the many examples of 
its demonstrable value and the efforts that various groups have already made towards enabling data 
sharing.7 However, a more nuanced approach to increasing IPD availability may be required. For 
example, further work is needed to clarify what is meant by IPD and when and how different data 
types and different levels of granularity should be made available.10  
  
Access to data from research is an important element in improving trials, particularly as permanent 
data loss occurs rapidly - at about 17% per year.33 Without concurrent work on making the many 
other elements available, inappropriate emphasis on making IPD available may prove an expensive 
distraction, and even counterproductive. The priorities identified in this article all offer potentially 
high yield on investment – they are simple, non-controversial, require minimal changes to existing 
systems, and some are already required for some categories of trials. Obtaining reliable summary 
data for all trials offers greater public benefit than obtaining all the data for a minority of trials.  
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Key Messages 
• Individual Participant Data (IPD) sharing can be valuable, but it is unhelpful to 
promote it at the expense of simpler and more cost-efficient measures that are part 
of the data sharing package and crucial to trial transparency and use. 
• Priorities that are more efficient than IPD sharing include requiring and enforcing 
prospective trial registration, and publication of summary results, protocols, and 
other trial materials from all controlled trials. 
• These priorities apply to trials of any intervention, not just to trials of drugs, 
biologics, and devices.  
• Access to IPD is an important element in improving the information yield from 
trials, but without concurrent efforts to make the many other elements available for 
all trials, promoting access to IPD may prove an expensive distraction, or even 
counterproductive.  
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